Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 15/20 | 0.44 |
| ▸ | USP2 | O75604 | 13/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.44 |
| ▸ | CASP1 | P29466 | 12/20 | 0.44 |
| ▸ | CASP7 | P55210 | 12/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923270 | 0.92 | WDR5 (0.43) | CYP1A2USP2ALDH1A1CASP1CASP7 | |
| SCHEMBL8267649 | 0.92 | MAPT (0.40) | ALDH1A1LMNAMAPTHPGDCCKAR | |
| SCHEMBL11923223 | 0.91 | PTPN11 (0.43) | CYP1A2USP2ALDH1A1CASP1CASP7 | |
| SCHEMBL11923212 | 0.86 | PIK3CA (0.38) | CYP1A2USP2ALDH1A1CASP1CASP7 | |
| SCHEMBL8267659 | 0.86 | WDR5 (0.44) | TP53MAPTWDR5 | |
| SCHEMBL8266903 | 0.85 | OGA (0.38) | MEN1KMT2ATSHRTP53WDR5 | |
| SCHEMBL8266650 | 0.85 | AOC3 (0.37) | CYP1A2USP2ALDH1A1CASP1CASP7 | |
| SCHEMBL11923170 | 0.84 | CCNE1 (0.38) | LMNAMAPTHPGDCCKAR | |
| SCHEMBL11923275 | 0.84 | TACR1 (0.40) | WDR5 | |
| SCHEMBL11923253 | 0.83 | MAPT (0.40) | CYP1A2ALDH1A1HSD17B10LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546414-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546414-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120270318-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270318-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-8236815-B2 | Ion channel modulators and methods of uses | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236815-B2 | Ion channel modulators and methods of uses | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-07 | — | — | US | disclosed |
| US-7767680-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767680-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100184753-A1 | Ion Channel Modulators and Methods of Uses | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184753-A1 | Ion Channel Modulators and Methods of Uses | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184753-A1 | Ion Channel Modulators and Methods of Uses | CACNA1G, CACNA1C, CACNA1B | CYP1A2 4154/4885USP2 3836/4885ALDH1A1 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.